Cigna eases burden of high cost gene therapies; plan doesn’t account for lack of benefit

As the Medicaid best price rule continues to stymie attempts to move beyond one-time payments for gene therapies, some payers and pharmacy benefit managers are working to soften the blow for their clients and patients. A new model announced by Cigna would allow employers to opt into a new benefit design that would spread the costs to the employer out over time, but does not address what happens when and if

Read the full 719 word article

User Sign In